Quest Diagnostics today said that it is now offering a molecular diagnostic test that can detect chromosome abnormalities associated with 85 developmental disorders affecting children.
 
The ClariSure is a microarray-based comparative genomic hybridization test that will be used to diagnose patients with mental retardation and Down syndrome among other disorders. Quest said it expects to provide physicians with test results within five days of receiving specimens at one of its facilities.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.